var title_f17_13_17616="In-toeing and out-toeing";
var content_f17_13_17616=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    In-toeing and out-toeing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 491px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In-toeing (upper panel) is a rotational variation in which the feet or toes point toward the midline during gait. Out-toeing (lower panel) is a rotational variation in which the feet or toes point away from the midline during gait.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_13_17616=[""].join("\n");
var outline_f17_13_17616=null;
var title_f17_13_17617="Clostridia in muscle";
var content_f17_13_17617=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clostridia in muscle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tissue gram stain of muscle biopsy (x400) from a patient with gas gangrene shows numerous Gram positive bacilli. Clostridium perfringens grew from this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Calderwood, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_13_17617=[""].join("\n");
var outline_f17_13_17617=null;
var title_f17_13_17618="Congenital epulis";
var content_f17_13_17618=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital epulis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Epulis is a congenital granular cell tumor that arises from the mucosa of the gingiva, usually from the anterior part of the maxillary alveolar ridge. Large lesions may interfere with breathing or feeding and require excision.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_13_17618=[""].join("\n");
var outline_f17_13_17618=null;
var title_f17_13_17619="Basic case 8 with answer";
var content_f17_13_17619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Atrial flutter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 112px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atrial flutter (at an atrial rate of approximately 240 beats/min) with a variable degree of atrioventricular block. The typical flutter (F) waves have a uniform, sawtooth appearance and occur at regular intervals which distinguish them from irregular fibrillatory waves in atrial fibrillation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_13_17619=[""].join("\n");
var outline_f17_13_17619=null;
var title_f17_13_17620="Altretamine: Patient drug information";
var content_f17_13_17620=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Altretamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/48/21253?source=see_link\">",
"     see \"Altretamine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hexalen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hexalen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700194",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood cell counts and an exam of your nerves will done before and after care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692002",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ovarian cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to altretamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703417",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bone marrow disease or nerve problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698222",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low white blood cell count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698275",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. You may need drugs to lower this side effect. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695845",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take after meals and at bedtime.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10744 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-30319E2B35-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_13_17620=[""].join("\n");
var outline_f17_13_17620=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132346\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132347\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025388\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025390\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025389\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025394\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025395\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025397\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025392\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025393\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025398\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025399\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/48/21253?source=related_link\">",
"      Altretamine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_13_17621="Perindopril: Patient drug information";
var content_f17_13_17621=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Perindopril: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=see_link\">",
"     see \"Perindopril: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aceon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Perindopril&reg;;",
"     </li>",
"     <li>",
"      Coversyl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691388",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help heart function after a heart attack.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to perindopril erbumine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703375",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A block in the kidneys' arteries or very bad kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695894",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take right before a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10967 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-EF161DC620-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_13_17621=[""].join("\n");
var outline_f17_13_17621=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208422\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208423\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020737\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020739\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020738\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020743\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020744\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020746\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020741\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020742\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020747\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020748\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/32/22024?source=related_link\">",
"      Perindopril: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_13_17622="Buprenorphine and naloxone: Patient drug information";
var content_f17_13_17622=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Buprenorphine and naloxone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/51/24375?source=see_link\">",
"     see \"Buprenorphine and naloxone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/5/41046?source=see_link\">",
"     see \"Buprenorphine and naloxone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Suboxone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13143399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Suboxone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700533",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Suboxone&reg; is only used to treat drug addiction.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat drug addiction and withdrawal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701663",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to buprenorphine, naloxone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697334",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have prostate disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698651",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Too much sweat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2893420",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <span style=\"text-decoration: underline\">",
"        <b>",
"         Under the tongue (sublingual) film:",
"        </b>",
"       </span>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2893439",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Open right before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2893441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wet mouth with water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2893442",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place film under your tongue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2893459",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If using 2 films, place on opposite sides. Try not to let films touch.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2898979",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If using 3 films, place the third film under the tongue after the first 2 films have melted.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696380",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not chew or swallow.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2893560",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         <b>",
"          Under the tongue (sublingual) tablet:",
"         </b>",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2893561",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place on the tongue and let melt.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699657",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any unused drug by flushing down a toilet or sink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11501 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-A7B94B43F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_13_17622=[""].join("\n");
var outline_f17_13_17622=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143145\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13143399\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017680\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017682\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017681\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017686\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017687\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017689\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017684\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017685\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017690\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017691\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/51/24375?source=related_link\">",
"      Buprenorphine and naloxone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/5/41046?source=related_link\">",
"      Buprenorphine and naloxone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_13_17623="Dobutamine stress CMR predicts viable myocardium";
var content_f17_13_17623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56784%7ECARD%2F68495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56784%7ECARD%2F68495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dobutamine stress CMR predicts viable myocardium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dobutamine stress CMR studies in a patient with total occlusion of the left anterior descending artery and a prior anterior wall myocardial infarction.",
"    <br>",
"     (Left upper panel) At rest, the short axis cine CMR at end-diastole shows normal diastolic wall thickness (*).",
"     <br>",
"      (Left lower panel) During systole (left lower panel) there is lack of systolic wall thickening (SWT) of the septum and anteroseptal portion of the anterior wall (arrow).",
"      <br>",
"       (Middle lower panel) During a dobutamine infusion, there was significant induction of SWT (arrow), indicating viable myocardium.",
"       <br>",
"        (Right lower panel) Four months after angioplasty, resting SWT of the anteroseptal region was normal.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         Reprinted with permission from: the American College of Cardiology (Journal of the American College of Cardiology) 1998; 31:1040.",
"        </div>",
"        <div class=\"contractual\">",
"         <br/>",
"         <a href=\"file://www.elsevier.com/locate/jacc\">",
"          file://www.elsevier.com/locate/jacc",
"         </a>",
"         <br/>",
"         <a href=\" file://www.sciencedirect.com\">",
"          file://www.sciencedirect.com",
"         </a>",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dobutamine stress CMR predicts lack of viable myocardium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 202px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dobutamine stress CMR studies in a patient with three vessel disease and a prior anterior wall myocardial infarction.",
"    <br>",
"     (Left upper panel) At rest, the short axis CMR during diastole shows that the diastolic wall thickness (DWT) of the anteroseptal wall is significantly reduced (arrows).",
"     <br>",
"      (Left lower panel) The entire region shows a lack of systolic wall thickening (SWT).",
"      <br>",
"       (Middle lower panel) During a dobutamine infusion, there was no measurable increase in SWT of the anteroseptal wall, indicating scar tissue.",
"       <br>",
"        (Right upper and lower panel) Six months after successful bypass surgery (CABG), the reduction in DWT persisted (arrows, upper panel) there was no improvement in SWT.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         Reprinted with permission from: The American College of Cardiology (Journal of the American College of Cardiology 1998; 31:1040).",
"        </div>",
"        <div class=\"contractual\">",
"         <br/>",
"         <a href=\"file://www.elsevier.com/locate/jacc\">",
"          file://www.elsevier.com/locate/jacc",
"         </a>",
"         <br/>",
"         <a href=\" file://www.sciencedirect.com\">",
"          file://www.sciencedirect.com",
"         </a>",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_13_17623=[""].join("\n");
var outline_f17_13_17623=null;
var title_f17_13_17624="Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Pediatric drug information";
var content_f17_13_17624=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34488?source=see_link\">",
"    see \"Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20017?source=see_link\">",
"    see \"Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adacel&reg;;",
"     </li>",
"     <li>",
"      Boostrix&reg;;",
"     </li>",
"     <li>",
"      Daptacel&reg;;",
"     </li>",
"     <li>",
"      Infanrix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F161262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adacel&reg;;",
"     </li>",
"     <li>",
"      Boostrix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34488?source=see_link\">",
"      see \"Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Primary Immunization:",
"     </b>",
"     Infants and Children &le;10 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children 6 weeks to &lt;7 years:",
"     <b>",
"      Note:",
"     </b>",
"     Whenever possible, the same product should be used for all doses. Interruption of recommended schedule does not require starting the series over; a delay between doses should not interfere with final immunity. Preterm infants should be vaccinated according to their chronological age from birth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Daptacel&reg;, Infanrix&reg;: I.M.: 0.5 mL per dose, total of 5 doses administered as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Three doses, usually given at 2-, 4-, and 6 months of age; may be given as early as 6 weeks of age and repeated every 4-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Fourth dose: Given at ~15-20 months of age, but at least 6 months after third dose. The fourth dose may be given as early as 12 months of age, but at least 6 months must have elapsed between the third dose and the fourth dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Fifth dose: Given at 4-6 years of age, prior to starting school or kindergarten; if the fourth dose is given at &ge;4 years of age, the fifth dose may be omitted",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and children who start primary immunization series &ge;4 months of age through 6 years (prior to 7th birthday) (ACIP \"Catch-up Immunization Schedule): Daptacel&reg;, Infanrix&reg;: I.M.: 0.5 mL per dose, total of 4-5 doses administered as: 3 doses at least 4 weeks apart followed 6 months later with dose 4; a 5th dose may be given 6 months later (the 5th dose is not necessary if the child received the 4th dose after 4 years of age)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 7-10 years not fully vaccinated against pertussis, or never vaccinated against diphtheria, tetanus, or pertussis, or whose vaccination status is not known: First dose: Adacel&reg;, Boostrix&reg;: I.M.: 0.5 mL per dose; followed by a series of 2 vaccinations containing tetanus and diphtheria toxoids [CDC, 60(1), 2011]. Tdap can be administered regardless of the interval between the last tetanus or diphtheria toxoid containing vaccine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Booster Immunization:",
"     </b>",
"     Children &ge;11 years, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     ACIP recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children and Adolescents 11-18 years: Adacel&reg;, Boostrix&reg;: I.M.: 0.5 mL per dose; Tdap should be given as a single booster dose at age 11 or 12 years in children who have completed a childhood vaccination series, followed by booster doses of Td every 10 years. Children who have not received Tdap at age 11 or 12 should receive a single dose of Tdap in place of a single Td booster dose [CDC, (55)3, 2006; CDC, (60)1, 2011].",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults &ge;19 years: Adacel&reg;, Boostrix&reg;: I.M.: 0.5 mL per dose. A single dose of Tdap should be given to replace a single dose of the 10 year Td booster in patients who have not previously received Tdap or for whom vaccine status is not known. A single dose of Tdap is recommended for healthcare personnel who have not previously received Tdap and who have direct patient contact [CDC, 55(17), 2006]. Tdap should be administered regardless of interval since last tetanus- or diphtheria-containing vaccine [CDC, 61(25), 2012].",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Manufacturer's labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;10 years, Adolescents, and Adults (Boostrix&reg;): I.M.: 0.5 mL as a single dose, administered 5 years after last dose of tetanus toxoid, diphtheria toxoid, and/or pertussis-containing vaccine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;11 years, Adolescents, and Adults &le;64 years (Adacel&reg;): I.M.: 0.5 mL as a single dose, administered 5 years after last dose of tetanus toxoid, diphtheria toxoid, and/or pertussis containing vaccine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tetanus prophylaxis in wound management:",
"     </b>",
"     Children &ge;7 years, Adolescents, and Adults: Adacel&reg;, Boostrix&reg;: I.M.: 0.5 mL as a single dose may be used as an alternative to Td vaccine when a tetanus toxoid-containing vaccine is needed for wound management, and in whom the pertussis component is also indicated. Tetanus prophylaxis in patients with wounds should consider if the wound is clean or contaminated, the immunization status of the patient, proper use of tetanus toxoid and/or tetanus immune globulin (TIG), wound cleaning, and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow-up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive a tetanus toxoid-containing vaccine until &gt;10 years after the most recent dose even if they have a wound that is neither clean nor minor. See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption>",
"      Tetanus Prophylaxis Wound Management",
"     </caption>",
"     <col align=\"center\" width=\"250\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <thead>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         History of Tetanus Immunization (Doses)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Clean, Minor Wounds",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         All Other Wounds",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Such as, but not limited to, wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; wounds from crushing, tears, burns, and frostbite.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          2",
"         </sup>",
"         Tetanus toxoid in this chart refers to a tetanus toxoid containing vaccine. For children &lt;7 years old DTaP (DT, if pertussis vaccine contraindicated) is preferred to tetanus toxoid alone. For children &ge;7 years of age and Adults, Td preferred to tetanus toxoid alone; Tdap may be preferred if the patient has not previously been vaccinated with Tdap.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          3",
"         </sup>",
"         Yes, if &ge;10 years since last dose.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          4",
"         </sup>",
"         Yes, if &ge; 5 years since last dose.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         Abbreviations:",
"         <b>",
"          DT",
"         </b>",
"         = Diphtheria and Tetanus Toxoids (formulation for age &le;6 years);",
"         <b>",
"          DTaP",
"         </b>",
"         = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (formulation for age &le;6 years; Daptacel&reg;, Infanrix&reg;);",
"         <b>",
"          Td",
"         </b>",
"         = Diphtheria and Tetanus Toxoids (formulation for age &ge;7 years; Tenivac&trade;);",
"         <b>",
"          TT",
"         </b>",
"         = Tetanus toxoid (adsorbed [formulation for age &ge;7 years]);",
"         <b>",
"          Tdap",
"         </b>",
"         = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (Adacel&reg; or Boostrix&reg; [formulations for age &ge;7 years]);",
"         <b>",
"          TIG",
"         </b>",
"         = Tetanus Immune Globulin",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         Adapted from the Yellow Book 2010, Chapter 2,",
"         <i>",
"          Routine Vaccine-Preventable Diseases, Tetanus",
"         </i>",
"         ; Available at www.cdc.gov/yellowbook;  and",
"         <i>",
"          MMWR",
"         </i>",
"         , 2006, 55:RR-17.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody>",
"      <tr>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Tetanus toxoid",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         TIG",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Tetanus toxoid",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         TIG",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Uncertain or &lt;3 doses",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Yes",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Yes",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Yes",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         3 or more doses",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"         <sup>",
"          3",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"         <sup>",
"          4",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F161248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension [Tdap, booster formulation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adacel&reg;: Diphtheria 2 Lf units, tetanus 5 Lf units, and acellular pertussis antigens [detoxified pertussis toxin 2.5 mcg, filamentous hemagglutinin 5 mcg, pertactin 3 mcg, fimbriae (types 2 and 3) 5 mcg] per 0.5 mL (0.5 mL) [contains aluminum; may contain natural rubber/natural latex in prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Boostrix&reg;: Diphtheria 2.5 Lf units, tetanus 5 Lf units, and acellular pertussis antigens [inactivated pertussis toxin 8 mcg, filamentous hemagglutinin 8 mcg, pertactin 2.5 mcg] per 0.5 mL (0.5 mL) [contains aluminum and polysorbate 80; may contain natural rubber/natural latex in prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension [DTaP, active immunization formulation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Daptacel&reg;: Diphtheria 15 Lf units, tetanus 5 Lf units, and acellular pertussis antigens [detoxified pertussis toxin 10 mcg, filamentous hemagglutinin 5 mcg, pertactin 3 mcg, fimbriae (types 2 and 3) 5 mcg] per 0.5 mL (0.5 mL) [preservative free; contains aluminum]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infanrix&reg;: Diphtheria 25 Lf units, tetanus 10 Lf units, and acellular pertussis antigens [inactivated pertussis toxin 25 mcg, filamentous hemagglutinin 25 mcg, pertactin 8 mcg] per 0.5 mL (0.5 mL) [preservative free; contains aluminum and polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infanrix&reg;: Diphtheria 25 Lf units, tetanus 10 Lf units, and acellular pertussis antigens [inactivated pertussis toxin 25 mcg, filamentous hemagglutinin 25 mcg, pertactin 8 mcg] per 0.5 mL (0.5 mL) [preservative free; contains aluminum and polysorbate 80; prefilled syringes contain natural rubber/natural latex] [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F161236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake vial well before withdrawing the dose; administer I.M. in either the anterolateral aspect of the thigh (Daptacel&reg;, Infanrix&reg;) or deltoid muscle of the arm (Boostrix&reg;, Adacel&reg;);",
"     <b>",
"      not for I.V., intradermal, or SubQ administration",
"     </b>",
"     . Adolescents and adults should be vaccinated while seated or lying down. U.S. law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F); do not freeze; discard if frozen. The following stability information has also been reported for Infanrix&reg;: May be stored at room temperature for up to 72 hours (Cohen, 2007). Tripedia&reg; may be used to reconstitute ActHIB&reg; for children &ge;15 months of age",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Daptacel&reg;, Infanrix&reg;: Active immunization for prevention of diphtheria, tetanus, and pertussis (FDA approved in ages 6 weeks through 6 years); has also been used for wound management for the prevention of tetanus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adacel&reg;: Active booster immunization for prevention of diphtheria, tetanus, and pertussis (FDA approved in ages 11-64 years); the Advisory Committee on Immunization Practices (ACIP) recommends a single dose for adults 19-64 years [this vaccine replaces tetanus and diphtheria toxoids (Td) vaccine if the individual has received the last dose of Td &ge;10 years earlier and has not previously received Tdap], adults who have or who anticipate having close contact with an infant &lt;12 months, healthcare personnel who have direct patient contact, and persons wounded in bombings or similar mass casualty events who cannot confirm receipt of a tetanus booster within the last 5 years and who have penetrating injuries or nonintact skin exposure; has also been used for wound management for the prevention of tetanus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Boostrix&reg;: Active booster immunization for prevention of diphtheria, tetanus, and pertussis (FDA approved in ages &ge;10 years); has also been used for wound management for the prevention of tetanus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children 6 weeks to &lt;7 years (DTaP):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; For primary immunization against diphtheria, tetanus, and pertussis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; Pediatric patients wounded in bombings or similar mass casualty events, have penetrating injuries or nonintact skin exposure, and have an uncertain vaccination history should receive a tetanus booster with DTaP (if no contraindications exist) (CDC, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 7-10 years (Tdap):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; Children not fully vaccinated against pertussis should receive a single dose of Tdap (if no contraindications exist) (CDC, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; Children never vaccinated against diphtheria, tetanus, or pertussis, or whose vaccination status is not known should receive a series of three vaccinations containing tetanus and diphtheria toxoids and the first dose should be with Tdap (CDC, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;11 years and Adolescents (Tdap):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; A single dose of Tdap as a booster dose in adolescents who have completed the recommended childhood DTaP vaccination series (preferred age of administration is 11-12 years) (CDC Vol 60 No 1, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;11 years, Adolescents, and Adults (Tdap):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; Persons wounded in bombings or similar mass casualty events and who cannot confirm receipt of a tetanus booster within the previous 5 years and who have penetrating injuries or nonintact skin exposure should receive a single dose of Tdap (CDC, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescent and Adult females: Pregnant females should receive a single dose with each pregnancy, preferably between 27-36 weeks gestation (CDC, 2013a; CDC, 2013b)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults &ge;19 years (including adults &ge;65 years) (Tdap): A single dose of Tdap should be given to all patients who have not previously received Tdap or for whom their vaccine status is unknown (CDC 2013a). Following administration of Tdap, Td vaccine should be used for routine boosters [CDC, 61(25), 2012]. The following patients, who have not yet received Tdap or for whom vaccine status is not known, should receive a single dose of Tdap as soon as feasible:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; Close contacts of children &lt;12 months of age: Tdap should ideally be administered at least 2 weeks prior to beginning close contact [CDC, 55(RR17), 2006; CDC, 60(41), 2011]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &bull; Healthcare providers with direct patient contact [CDC, 55(RR17), 2006; CDC, 61(4), 2012]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Tdap is currently recommended for a single dose only (all age groups) (CDC, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2671735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Adacel&reg; (Tdap) may be confused with Daptacel&reg; (DTaP)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tdap (Adacel&reg;, Boostrix&reg;) may be confused with DTaP (Daptacel&reg;, Infanrix&reg;, Tripedia)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Carefully review product labeling to prevent inadvertent administration of Tdap when DTaP is indicated. Tdap contains lower amounts of diphtheria toxoid and some pertussis antigens than DTaP.",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;\">",
"       Tdap is not indicated for use in children &lt;10 years of age",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;\">",
"       DTaP is not indicated for use in persons &ge;7 years of age",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Guidelines are available in case of inadvertent administration of these products; refer to ACIP recommendations, February 2006 available at",
"       <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr55e223a1.htm\" target=\"_blank\">",
"        file://www.cdc.gov/mmwr/preview/mmwrhtml/rr55e223a1.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       DTaP: Diphtheria and tetanus toxoids and acellular pertussis vaccine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       DTP: Diphtheria and tetanus toxoids and pertussis vaccine (unspecified pertussis antigens)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       DTwP: Diphtheria and tetanus toxoids and whole-cell pertussis vaccine (no longer available on U.S. market)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"       Tdap: Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F161277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Daptacel&reg;, Infanrix&reg;",
"     </b>",
"     (incidence of erythema, swelling, and fever increases with successive doses):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drowsiness, fever, fussiness, irritability, lethargy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Appetite decreased, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain, redness, swelling, tenderness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Prolonged or persistent crying, refusal to play",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reaction, anaphylactic reactions, angioedema, apnea, bronchitis, cellulitis, cough, cyanosis, diarrhea, ear pain, encephalopathy, erythema, fatigue, headache, hypersensitivity, hypotonia, hypotonic-hyporesponsive episode, idiopathic thrombocytopenic purpura, infantile spasm, injection site reaction (abscess, cellulitis, induration, mass, nodule, rash), intussusception, limb swelling, lymphadenopathy, nausea, pruritus, rash, respiratory tract infection, seizure, screaming, somnolence, sudden infant death syndrome, thrombocytopenia, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Adacel&reg;; Boostrix&reg;:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, fatigue/tiredness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Gastrointestinal symptoms, includes abdominal pain, diarrhea, nausea and/or vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Arm circumference increased, injection site pain, redness, swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Body aches/muscle weakness, soreness/swollen joints",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Lymph node swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Rare but important or life-threatening:  Anaphylactic reaction, arthralgia, back pain, diabetes mellitus, encephalitis, exanthema, facial palsy, GBS, Henoch-Sch&ouml;nlein  purpura, hypersensitivity reactions, hypoesthesia, injection site reaction (bruising, induration, inflammation, mass, nodule, pruritus, sterile abscess, warmth), limb swelling (extensive), lymphadenitis, lymphadenopathy, myalgia, myocarditis, myositis, nerve compression, paresthesia, pruritus, seizure, syncope, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component; encephalopathy occurring within 7 days of administration of a previous dose of a pertussis-containing vaccine that is not attributable to another cause; progressive neurological disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy; (pertussis vaccine should be withheld until the clinical condition has stabilized)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute severe febrile illness; may administer to patients with mild acute illness (with or without fever). Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy, including high-dose corticosteroids); may have a reduced response to vaccination and vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (CDC, 2011). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A family history of seizures is not a contraindication to use of DTaP. Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009). Administer with caution to patients with thrombocytopenia or any coagulation disorder that would be compromised by I.M. injection; if the patient receives antihemophilia or other similar therapy, I.M. injection can be scheduled shortly after such therapy is administered. Some products contain latex; persons sensitive to latex should avoid contact.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate treatment for anaphylactoid or acute hypersensitivity reactions should be available during vaccine use. Subsequent vaccination with a pertussis containing vaccine should be carefully considered if the following reactions occur with a temporal relationship to a previous dose of any pertussis-containing vaccine: Temperature &ge;40.5&deg;C (105&deg;F) within 48 hours, not attributable to another identifiable cause, collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours, persistent crying lasting &ge;3 hours within 48 hours, or convulsions with or without fever occurring within 3 days. Guillain-Barr&eacute; syndrome occurring within 6 weeks of vaccines containing tetanus toxoid has been reported. Tetanus toxoid containing vaccine (including emergency doses) should not be given more frequently than every 10 years in patients who have experienced a serious Arthus-type hypersensitivity reaction following a prior use of tetanus toxoid even if using for wound management with wounds that are not clean or minor; these patients generally have high serum antitoxin levels. These patients generally have high serum antitoxin concentrations. Boostrix&reg; and Adacel&reg; contain reduced antigens and are not indicated for use in the primary vaccine series (ages 6 weeks to 6 years). Apnea has occurred following intramuscular vaccine administration in premature infants; consider clinical status implications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injection may contain polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986;",
"     <i>",
"      MMWR",
"     </i>",
"     , 1984).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F161243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F161245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B/C (manufacturer specific) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F161256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with all products; when conducted, adverse effects to the fetus were not observed in developmental toxicity studies. Inactivated bacterial vaccines have not been shown to cause increased risks to the fetus (CDC, 60[2], 2011). Daptacel&reg; and Infanrix&reg; are not recommended for use in a pregnant woman or any patient &ge;7 years of age. Using data collected from 2005-2010 VAERS, there were not any patterns of adverse maternal, fetal, or neonatal outcomes identified following maternal use of the Tdap vaccine (Zheteyeva, 2012). All pregnant females should receive a single dose of Tdap during each pregnancy, regardless of previous vaccination status, preferably between 27-36 weeks gestation. Alternately, administration of Tdap can be given immediately postpartum to all women who have not previously been vaccinated with Tdap in order to protect the mother and infant from pertussis (CDC, 62[7], 2013).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Pregnancy registries have been established for women who may become exposed to Boostrix&reg; (888-452-9622) or Adacel&reg; (800-822-2463) while pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10160896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion. Adolescents and adults should be vaccinated while seated or lying down.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1058021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adacel&reg; is formulated with the same antigens found in Daptacel&reg; but with reduced quantities of tetanus and pertussis; Boostrix&reg; is formulated with the same antigens found in Infanrix&reg; but in reduced quantities. Use of Adacel&reg; or Boostrix&reg; in the primary immunization series or to complete the primary series has not been evaluated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The ACIP considers Adacel&reg; and Boostrix&reg; to be interchangeable when administered to adolescents for childhood vaccination according to the Child and Adolescent Immunization Schedule.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Adults Aged 19 Years and Older - United States, 2013,\"",
"      <i>",
"       MMWR Surveill Summ",
"      </i>",
"      , 2013b, 62(1):9-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/23364303/pubmed\" id=\"23364303\" target=\"_blank\">",
"        23364303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Persons Aged  0 through 18 Years - United States, 2013,\"",
"      <i>",
"       MMWR Surveill Summ",
"      </i>",
"      , 2013a, 62(1):2-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/23364302/pubmed\" id=\"23364302\" target=\"_blank\">",
"        23364302",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;FDA Approval of Expanded Age Indication for a Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2009, 58(14):374-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/19373199/pubmed\" id=\"19373199\" target=\"_blank\">",
"        19373199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"General Recommendations on Immunization-Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/ 21293327 /pubmed\" id=\" 21293327 \" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Notice to Readers: Update: Supply of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine,&rdquo;",
"      <i>",
"       MMWR",
"      </i>",
"      , 2002, 50(51):1159.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Preventing Tetanus, Diphtheria, and Pertussis Among Adolescents: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccines Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-3):1-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/16557217/pubmed\" id=\"16557217\" target=\"_blank\">",
"        16557217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Preventing Tetanus, Diphtheria, and Pertussis Among Adults: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Recommendations of the Advisory Committee on Immunization Practices (ACIP) and Recommendation of ACIP, Supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for Use of Tdap Among Health-Care Personnel,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-17):1-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/17167397/pubmed\" id=\"17167397\" target=\"_blank\">",
"        17167397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Contro and Prevention (CDC), &ldquo;Recommendations for Postexposure Interventions to Prevent Infection With Hepatitis B Virus, Hepatitis C Virus, or Human Immunodeficiency Virus, and Tetanus in Persons Wounded During Bombings and Other Mass-Casualty Events -- United States, 2008: Recommendations of the Centers For Disease Control and Prevention (CDC),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2008, 57(RR-6):1-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/18668022/pubmed\" id=\"18668022\" target=\"_blank\">",
"        18668022",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/18451756 /pubmed\" id=\"18451756 \" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine From the Advisory Committee on Immunization Practices, 2010,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(1):13-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/21228763/pubmed\" id=\"21228763\" target=\"_blank\">",
"        21228763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine in Adults Aged 65 Years and Older - Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2012, 61(25):468-470.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/22739778/pubmed\" id=\"22739778\" target=\"_blank\">",
"        22739778",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap) in Pregnant Women and Persons Who Have or Anticipate Having Close Contact With an Infant Aged &lt;12 Months --- Advisory Committee on Immunization Practices (ACIP), 2011&rdquo;,",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      2011, 60(41):1424-26.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers For Disease Control and Prevention (CDC), &ldquo;Use of Diphtheria Toxoid-Tetanus Toxoid-Acellular Pertussis Vaccine as a Five-Dose Series,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2000, 49(RR-13):1-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/11106289/pubmed\" id=\"11106289\" target=\"_blank\">",
"        11106289",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Vaccines for Children Program, \"Vaccines to Prevent Diphtheria, Tetanus and Pertussis,\" Resolution No. 6/11-2. Available at",
"      <a href=\"file://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/0611dtap.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/0611dtap.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/19373199/pubmed\" id=\"19373199\" target=\"_blank\">",
"        19373199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chapman LE, Sullivent EE, Grohskopf LA, et al, \"Recommendations for Postexposure Interventions to Prevent Infection With Hepatitis B Virus, Hepatitis C Virus, or Human Immunodeficiency Virus, and Tetanus in Persons Wounded During Bombings and Other Mass-Casualty Events--United States, 2008: Recommendations of the Centers for Disease Control and Prevention (CDC),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2008, 57(RR-6):1-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/18668022/pubmed\" id=\"18668022\" target=\"_blank\">",
"        18668022",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kretsinger K, Broder KR, Cortese MM, et al, \"Preventing Tetanus, Diphtheria, and Pertussis Among Adults: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-17):1-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/17167397/pubmed\" id=\"17167397\" target=\"_blank\">",
"        17167397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murphy TV, Slade BA, Broder KR, \"Prevention of Pertussis, Tetanus, and Diphtheria Among Pregnant and Postpartum Women and Their Infants,\"",
"      <i>",
"       MMWR",
"      </i>",
"      , 2008, 57(Early Release);1-47; available at file://www.cdc.gov/mmwr/preview/mmwrhtml/rr57e0514a1.htm?s_cid=rr57e0514a1_e.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zheteyeva YA, Moro PL, Tepper NK, et al, \"Adverse Event Reports After Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines in Pregnant Women,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2012, 207(1):59.e1-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/13/17624/abstract-text/22727350/pubmed\" id=\"22727350\" target=\"_blank\">",
"        22727350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12763 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-239B17CE44-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_13_17624=[""].join("\n");
var outline_f17_13_17624=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161261\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161262\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058014\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058008\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161248\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161236\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058018\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058011\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058017\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2671735\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161277\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058020\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058007\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058006\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299219\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161243\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161245\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161256\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10160896\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058021\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12763\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12763|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34488?source=related_link\">",
"      Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20017?source=related_link\">",
"      Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_13_17625="Amniotic bands";
var content_f17_13_17625=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69162%7EOBGYN%2F70926%7EOBGYN%2F63863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69162%7EOBGYN%2F70926%7EOBGYN%2F63863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amniotic bands",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Image of the extremities shows amniotic bands (arrows) stretching between the extremities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amniotic band sequence with cranial defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oblique axial image through the fetal head shows the orbits, but no ossified cranium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amniotic band sequence with abdominal wall defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal image through the fetal body shows disruption of the anterior abdominal wall with the abdominal contents (arrows) extruding out.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_13_17625=[""].join("\n");
var outline_f17_13_17625=null;
var title_f17_13_17626="Pharmacotherapy for smoking cessation in adults";
var content_f17_13_17626=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacotherapy for smoking cessation in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/13/17626/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/13/17626/contributors\">",
"     Stephen I Rennard, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/13/17626/contributors\">",
"     Nancy A Rigotti, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/13/17626/contributors\">",
"     David M Daughton, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/13/17626/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/13/17626/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/13/17626/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/13/17626/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/13/17626/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/13/17626/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13311124\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacotherapy for smoking cessation aims to reduce the symptoms of nicotine withdrawal, thereby making it easier for a smoker to stop the habitual use of cigarettes. The main medications that have demonstrated efficacy as smoking cessation aids include nicotine replacement,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    . Smoking cessation pharmacotherapy should be offered to all smokers making a quit attempt, unless medically contraindicated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since tobacco use is both a learned behavior and a physical addiction to nicotine for the majority of smokers, the combination of counseling and pharmacologic therapies can produce higher quit rates than either one alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacologic management to help patients stop smoking is reviewed here. An overview of smoking cessation management and behavioral methods of smoking cessation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13314630\">",
"    <span class=\"h1\">",
"     MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most effective medications for smoking cessation include nicotine replacement,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef60067 \" href=\"UTD.htm?25/45/26333\">",
"     table 1",
"    </a>",
"    ). Smoking cessation clinical guidelines from the United States Public Health Service consider seven drugs to be first-line agents for tobacco cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transdermal nicotine patch",
"     </li>",
"     <li>",
"      Nicotine gum",
"     </li>",
"     <li>",
"      Nicotine lozenge",
"     </li>",
"     <li>",
"      Nicotine inhaler",
"     </li>",
"     <li>",
"      Nicotine nasal spray",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       Bupropion",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"       Varenicline",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13311131\">",
"    <span class=\"h2\">",
"     Nicotine replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those wishing to use nicotine replacement therapy (NRT), we recommend the combined use of a long-acting and a short-acting nicotine replacement product as initial NRT. (See",
"    <a class=\"local\" href=\"#H606502060\">",
"     'Combination nicotine therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The goal of NRT is to provide nicotine to a smoker without using tobacco, thereby relieving nicotine withdrawal symptoms as the smoker breaks the behavior of cigarette smoking. The use of NRT in place of cigarettes avoids exposure to carbon monoxide that reduces oxygen delivery, to oxidant gases that are atherogenic, and to tars that are carcinogenic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18968?source=see_link\">",
"     \"Benefits and risks of smoking cessation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nicotine replacement products differ in their pharmacokinetics and delivery of nicotine to the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/2\">",
"     2",
"    </a>",
"    ]. Nicotine is absorbed transdermally with the nicotine patch, through the nasal mucosa by the nasal spray, or through the oral mucosa with the nicotine chewing gum, lozenge, or inhaler. No product delivers nicotine as rapidly as cigarette smoking, a factor that contributes specifically to the dependence-producing properties of cigarettes. The patch has a long-acting, slow-onset pattern of nicotine delivery, producing relatively constant withdrawal relief over 24 hours, but requiring several hours to reach peak levels. Compliance with the patch is high, but the user has no control of nicotine dose to respond to nicotine cravings and withdrawal symptoms during the day. By contrast, the nasal spray and oral forms of nicotine replacement (gum, lozenge, and inhaler) share a short-acting but rapid-onset pattern of nicotine delivery that allows the user flexibility to respond to acute cravings or withdrawal symptoms. However, the nasal and oral forms require repeated use throughout the day, lead to more variable nicotine levels, and require more instruction for correct use.",
"   </p>",
"   <p>",
"    Three NRT products are available in the US without a prescription (patch, lozenge, and gum). The other two (nasal spray and oral inhaler) are available by prescription only.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606502088\">",
"    <span class=\"h3\">",
"     Efficacy, dosing, duration, safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;In randomized trials, all five nicotine replacement products are superior to placebo, increasing quit rates approximately two-fold (",
"    <a class=\"graphic graphic_table graphicRef60067 \" href=\"UTD.htm?25/45/26333\">",
"     table 1",
"    </a>",
"    ), but few trials have directly compared one product to another in the same study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. One randomized trial found no difference in efficacy between the patch, gum, inhaler, and nasal spray [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/3\">",
"     3",
"    </a>",
"    ]. In some but not all trials, NRT benefits men more than women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Combinations of different nicotine replacement products are more effective than single product therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H606502060\">",
"     'Combination nicotine therapy'",
"    </a>",
"    below.) Relapse rates in smokers who quit with NRT are similar to rates in those who quit without NRT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dosing of most NRT products varies based on the number of cigarettes smoked daily. The dose of NRT is gradually tapered as nicotine withdrawal symptoms subside. In general, NRT use is recommended for two to three months. However, NRT use for a longer period of time is acceptable in patients with a high risk of smoking relapse.",
"   </p>",
"   <p>",
"    Smokers often worry that they will remain dependent on nicotine if they use these products when stopping smoking. This may occur, although it is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/1\">",
"     1",
"    </a>",
"    ]. The dose of nicotine delivered with NRT is smaller and the delivery of nicotine is slower than inhaled tobacco smoke, which prevent nicotine dependence.",
"   </p>",
"   <p>",
"    The specific side effect profile of NRT varies based on the individual nicotine replacement product, as discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/1\">",
"     1",
"    </a>",
"    ]. NRT products used in combination are safe as each agent produces lower blood nicotine levels than that produced by the average smoker who smokes a pack of cigarettes daily. In addition, if smokers do experience side effects, they can titrate the use of NRT products to minimize any adverse effects (in contrast to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Nicotine replacement is safe to use in patients with known cardiovascular disease (CVD) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]. As an example, one randomized trial of 584 outpatients with stable CVD found no significant difference between transdermal nicotine- and placebo-treated patients in the frequency of death, myocardial infarction, cardiac arrest, and hospital admission due to increased severity of angina, arrhythmia, or congestive heart failure during a 14 week study period [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/10\">",
"     10",
"    </a>",
"    ]. This and other studies have suggested that the risks of smoking while wearing a nicotine patch are not increased above the risks of smoking alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/23/30073?source=see_link&amp;anchor=H18#H18\">",
"     \"Cardiovascular effects of nicotine\", section on 'Safety of nicotine replacement therapy'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The initiation of NRT in patients after acute coronary syndromes is discussed elsewhere. It is likely that the benefits of nicotine replacement through smoking cessation outweigh any potential risks in most smokers with CVD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=see_link&amp;anchor=H36#H36\">",
"     \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\", section on 'Smoking cessation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7098?source=see_link&amp;anchor=H32#H32\">",
"     \"Overview of the non-acute management of ST elevation myocardial infarction\", section on 'Smoking cessation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13311138\">",
"    <span class=\"h4\">",
"     Transdermal nicotine patch",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nicotine patch is the simplest nicotine replacement product for a smoker to use and provides the most continuous nicotine delivery of all nicotine replacement products, but does not offer a smoker the option of adjusting nicotine exposure over the course of the day.",
"   </p>",
"   <p>",
"    Starting on the quit day, patients who smoke &gt;10",
"    <span class=\"nowrap\">",
"     cigarettes/day",
"    </span>",
"    (one-half pack) use the highest dose of the nicotine patch (21",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for six weeks, followed by 14",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for two weeks, and finish with 7",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for two weeks. Smokers who weigh less than 45 kg or smoke &le;10 cigarettes per day are advised to begin with the",
"    <span class=\"nowrap\">",
"     14-mg/day",
"    </span>",
"    strength for six weeks, followed by 7",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for two weeks.",
"   </p>",
"   <p>",
"    It is uncertain whether longer duration of treatment with the nicotine patch leads to improved smoking cessation rates. In a randomized trial of 3575 smokers, continuous abstinence rates did not differ significantly between 8 week versus 22 week therapy, regardless of dose (15 mg and 25 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/16\">",
"     16",
"    </a>",
"    ]. However, this may be due to the conservative outcome measure, which considers any relapse a treatment failure, despite subsequent recovery with rescue therapy. In another randomized trial of 568 smokers treated with nicotine 21 mg daily, extended therapy (24 weeks) was associated with higher rates of 7-day point-prevalence abstinence at 24 weeks (OR 1.81, 95% CI 1.23-2.66), compared to standard duration therapy (8 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/17\">",
"     17",
"    </a>",
"    ]. This study excluded patients with significant medical comorbidities, which may not be representative of the general smoking population.",
"   </p>",
"   <p>",
"    To use the nicotine patch, the smoker applies one patch each morning to any non-hairy skin site. It is removed and replaced with a new patch the next morning. The patch site should be rotated daily to avoid skin irritation, which is the most common side effect.",
"   </p>",
"   <p>",
"    Insomnia and vivid dreams are frequently reported when the patch is left on overnight. These can be minimized by removing the patch at bedtime. Smoking cessation rates are similar whether the patch is left on for 24 hours or taken off at night [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/18\">",
"     18",
"    </a>",
"    ]. If the patch is removed at night, substantial plasma levels of nicotine are reached 30 minutes to three hours after a new patch is applied in the morning [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients who remove the patch at night and experience morning cravings for nicotine can use a rapid-acting form of nicotine replacement therapy (eg, gum, lozenge) while waiting for the nicotine patch to take effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13311145\">",
"    <span class=\"h4\">",
"     Nicotine gum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nicotine gum contains nicotine bound to a polacrilex resin and a buffering agent. Tobacco withdrawal symptoms are generally not prevented by gum use alone, but the intensity of withdrawal is often reduced. In addition, as peak blood levels are much less than with a cigarette, both the euphoric effect and the addiction potential of nicotine gum are less than those of cigarettes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 4 mg dose of gum is recommended for smokers who smoke 25 or more cigarettes per day, whereas the 2 mg dose is recommended for lighter smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/1\">",
"     1",
"    </a>",
"    ]. Smokers are instructed to chew the gum whenever they have an urge to smoke. Chewing the gum releases nicotine that is absorbed through the oral mucosa, resulting in a peak of blood nicotine levels 20 minutes after starting to chew. Smokers can chew one piece of gum every 1 to 2 hours over six weeks, with a gradual reduction over a second six weeks, for a total duration of three months.",
"   </p>",
"   <p>",
"    Proper chewing of gum is important for optimal results. If the gum is chewed too rapidly, nicotine is released faster than it can be absorbed by the buccal mucosa and the nicotine is swallowed. Swallowed nicotine can cause gastric and esophageal irritation. Furthermore, nicotine absorbed from the gastrointestinal tract is largely metabolized by the liver and is therefore relatively ineffective. A \"chew and park\" pattern of gum use is recommended. A piece of gum is chewed until the nicotine taste appears, then \"parked\" in the buccal mucosa until the taste disappears. At this point, the gum is chewed a few more times to release more nicotine. This cycle is repeated for 30 minutes, at which point the gum is discarded because all of the nicotine in the gum has been released. Swallowed gum does not release nicotine well.",
"   </p>",
"   <p>",
"    Acidic beverages (eg, coffee, carbonated drinks) should be avoided before and during gum use, as acidic beverages lowers oral pH, causing nicotine to ionize and reducing nicotine absorption.",
"   </p>",
"   <p>",
"    Side effects are mostly a consequence of excess nicotine release with overly vigorous chewing, and consist of nausea, vomiting, abdominal pain, constipation, hiccups, headache, excess salivation, a sore jaw, and mouth irritation or ulcers. Chewing gum may exacerbate temporomandibular joint disease and can damage dental appliances. Smokers with temporomandibular joint disease, poor dentition, or those who use dental appliances should avoid use of nicotine gum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13311152\">",
"    <span class=\"h4\">",
"     Nicotine lozenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lozenge is an oral NRT with a pharmacokinetic profile similar to nicotine gum. In contrast to nicotine gum, the lozenge does not need to be chewed, making it easier to use. The lozenge can also be used in smokers with temporomandibular joint disease, poor dentition, or dentures.",
"   </p>",
"   <p>",
"    The lozenge is placed in the mouth and allowed to dissolve for 30 minutes. Like the gum, the lozenge is sold in 2 and 4 mg doses. The 4 mg dose is recommended for smokers who smoke within 30 minutes of awakening (a measure of greater nicotine dependence); the 2 mg dose is recommended for all other smokers. The dosing schedule is similar to that of the gum: one lozenge every 1 to 2 hours for six weeks, with a gradual reduction in the number of lozenges used per day over a second six weeks. The maximum dose is 5 lozenges every 6 hours or 20 lozenges per day.",
"   </p>",
"   <p>",
"    Adverse effects of the nicotine lozenge include mouth irritation or ulcers, abdominal pain, nausea, vomiting, diarrhea, headache, and palpitations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13311159\">",
"    <span class=\"h4\">",
"     Nicotine inhaler",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nicotine inhaler consists of a mouthpiece and a plastic, nicotine-containing cartridge. When the smoker inhales through the device, nicotine vapor (not smoke) is released and deposited in the oropharynx and absorbed through the oral mucosa. Nicotine vapor does not reach the lungs to an appreciable extent. The pharmacokinetics of the inhaler resemble those of nicotine gum. The inhaler addresses not only physical dependence, but also the behavioral and sensory aspects of smoking (ie, having a cigarette between one&rsquo;s fingers and inhaling from the cigarette). The ad lib use of the nicotine inhaler produces plasma nicotine levels that are roughly one-third of those that occur with cigarette smoking.",
"   </p>",
"   <p>",
"    The recommended dose of the nicotine inhaler is 6 to 16 cartridges per day for the first 6 to 12 weeks, followed by gradual reduction of dose over the next 6 to 12 weeks.",
"   </p>",
"   <p>",
"    Localized irritation of the mouth or throat is common, particularly during the early stages of use. Because inhaled nicotine may cause bronchospasm, it may be less appropriate for smokers with a history of severe airway reactivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13311166\">",
"    <span class=\"h4\">",
"     Nicotine nasal spray",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nicotine nasal spray delivers an aqueous solution of nicotine to the nasal mucosa. The nicotine nasal spray produces a more rapid rise in plasma nicotine concentration than orally-absorbed nicotine replacement products (gum, inhaler, lozenge), producing a peak of nicotine 10 minutes after use. Although the nasal spray more closely mimics changes seen with smoking, it does not deliver nicotine nearly as fast as smoking a cigarette [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One or two sprays per hour are recommended for about three months. The maximum dose is 10 sprays per hour or 80 total sprays per day.",
"   </p>",
"   <p>",
"    In clinical practice, its use is limited by the typical side effects of nasal and throat irritation, rhinitis, sneezing, and tearing. Nasal irritation is extremely common, occurring in 94 percent of patients during the first two days of use, and continuing in 81 percent of patients after three weeks of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606502060\">",
"    <span class=\"h4\">",
"     Combination nicotine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend the combined use of a long-acting and a short-acting nicotine replacement product as initial nicotine replacement therapy. The nicotine patch is the primary NRT product to control baseline nicotine withdrawal symptoms. Adding a short-acting form of NRT helps to control cravings and withdrawal symptoms during the day on an as needed basis. This has been called the \"patch plus\" regimen. The choice of a short-acting agent depends on patient preference and comorbidities.",
"   </p>",
"   <p>",
"    Randomized trials have found that combining the nicotine patch with the gum, inhaler, nasal spray, or lozenge has better efficacy than the use of a single product [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In a meta-analysis of 9 trials, the combination of nicotine patch with a short-acting NRT product (gum, spray or inhaler) was more effective than a single type of NRT alone (RR 1.34, 95% CI 1.18 to 1.51) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/23\">",
"     23",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13311180\">",
"    <span class=\"h2\">",
"     Bupropion",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    is effective for smoking cessation and is believed to act by enhancing central nervous system noradrenergic and dopaminergic release. A sustained-release formulation of the drug (Zyban) is licensed as an aid to smoking cessation; it is identical to the antidepressant Wellbutrin SR and sustained-release bupropion is available as a generic drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346565385\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 36 randomized trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    monotherapy found that bupropion nearly doubles the likelihood of smoking cessation, compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/24\">",
"     24",
"    </a>",
"    ]. As an example, one multicenter, randomized trial of 615 smokers compared sustained-release bupropion (150 mg twice daily) with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/25\">",
"     25",
"    </a>",
"    ]. The rates of point-prevalence abstinence (confirmed by exhaled carbon monoxide measurements) were greater at the end of a seven-week course of treatment among patients who received bupropion (44 versus 19 percent). After one year, many successful quitters were again smoking, but abstinence was still higher in the bupropion group (23 versus 12 percent). Similar results were seen in a trial conducted in general practitioner offices, suggesting that these results are applicable to primary care practice [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/26\">",
"     26",
"    </a>",
"    ]. Other studies have demonstrated the efficacy of bupropion in specific populations, including in African-American smokers, and in smokers who have stable CVD or chronic obstructive pulmonary disease (COPD) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in trials in patients hospitalized for acute myocardial infarction, buproprion was not effective for long-term smoking cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. As an example, in the largest trial, 393 patients post-myocardial infarction were randomized to buproprion or placebo for nine weeks and followed for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/31\">",
"     31",
"    </a>",
"    ]. At 12 months, point prevalence abstinence rates were 37 and 32 percent in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    and placebo group, respectively; continuous abstinence rates were 26.8 and 22.2 percent, respectively. One possible reason for the discrepancy between these trials and trials in the general population is the difference in the patient population studied. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346565378\">",
"    <span class=\"h3\">",
"     Dosing and duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since sustained-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    takes five to seven days to reach steady-state blood levels, it is started one week before a smoker's target quit date. The recommended dose is 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three days, then 150 mg twice a day thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/1\">",
"     1",
"    </a>",
"    ]. However, in two randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/25,33\">",
"     25,33",
"    </a>",
"    ], the 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    dose was as effective as the 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    dose and associated with fewer side effects. Thus, the lower dose is an option, especially for smokers who do not tolerate the full dose due to side effects.",
"   </p>",
"   <p>",
"    The recommended duration of treatment is 7 to 12 weeks. However, longer duration therapy may prevent relapse in successful quitters. A randomized trial of 461 smokers who successfully quit smoking after seven weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    therapy compared active ongoing treatment with bupropion 300 mg per day to placebo for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients were followed for two years, and self-reported abstinence was confirmed by monitoring levels of exhaled carbon monoxide. Active therapy had the following benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher abstinence rate at one year (51 versus 42 percent) that persisted 16 weeks after discontinuation of therapy (47 versus 37 percent);",
"     </li>",
"     <li>",
"      A longer median time to relapse after cessation of therapy (156 days versus 65 days);",
"     </li>",
"     <li>",
"      Less weight gain at two years (4.1 versus 5.4 kg).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, abstinence rate at two years was the same in both groups (41 versus 40 percent).",
"   </p>",
"   <p>",
"    Based on current evidence, we recommend treating with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    for at least 12 weeks. Longer duration treatment can be considered in individual cases, based on previous quit attempts and patient preference. However, if the rationale for longer treatment is improved mood, it is important to assess the change in depressive symptoms from the initiation of treatment and to make dosing adjustments accordingly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link&amp;anchor=H16#H16\">",
"     \"Initial treatment of depression in adults\", section on 'Antidepressants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13311187\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    are insomnia, agitation, dry mouth, and headache.",
"   </p>",
"   <p>",
"    A more serious side effect is seizure, which can occur because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    reduces the seizure threshold. In clinical trials of bupropion in smoking cessation, the risk of seizure was 0.1 percent. The risk of seizure with bupropion use is dose-dependent and is most often described in the setting of overdose",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in patients with other risk factors for seizures. The drug is contraindicated in patients with a seizure disorder or predisposition to seizure.",
"   </p>",
"   <p>",
"    In 2008, the US Food and Drug Administration (FDA) reported \"a possible association between suicidal events and the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    ,\" based upon review of post-marketing reports [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/35\">",
"     35",
"    </a>",
"    ]. Cases were reported even in individuals with no history of psychiatric disease and without concomitant psychiatric medications. Patients should be monitored for neuropsychiatric symptoms including changes in behavior, hostility, agitation, depressed mood, suicidal ideation, and suicide attempts. As with other smokers receiving treatment, we recommend that a follow-up visit be scheduled within three to seven days of the patient's quit day to monitor for adverse effects, as well as to assess response and provide reinforcement for smoking cessation (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link&amp;anchor=H13313727#H13313727\">",
"     \"Overview of smoking cessation management in adults\", section on 'Follow-up'",
"    </a>",
"    ). We agree with the FDA recommendation that patients be told to contact the office and stop the drug if they or their family notice any unusual behavior or mood symptoms. (See",
"    <a class=\"local\" href=\"#H13311208\">",
"     'Neuropsychiatric effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    is safe for use among smokers hospitalized for acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/30-32\">",
"     30-32",
"    </a>",
"    ], with stable CVD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/28\">",
"     28",
"    </a>",
"    ] and COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13311194\">",
"    <span class=\"h2\">",
"     Varenicline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     Varenicline",
"    </a>",
"    is effective for smoking cessation. Varenicline is a partial agonist at the alpha-4 beta-2 subunit of the nicotinic acetylcholine receptor, the receptor that appears to produce the reinforcing effects of nicotine and leads to nicotine dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Varenicline is hypothesized to aid smoking cessation in two ways. As a partial agonist, it binds to and produces partial stimulation of the alpha4beta2 nicotinic receptor, thereby reducing the symptoms of nicotine withdrawal. Secondly, since varenicline binds to the alpha4beta2 receptor subunit with high affinity, it blocks the nicotine in tobacco smoke from binding to the receptor, thereby reducing the rewarding aspects of cigarette smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346565392\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    for smoking cessation has been demonstrated in several randomized placebo-controlled trials conducted in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/39-43\">",
"     39-43",
"    </a>",
"    ], Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/44\">",
"     44",
"    </a>",
"    ], and Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/45\">",
"     45",
"    </a>",
"    ]. A 2012 meta-analysis of randomized trials found that continuous abstinence at six months or longer was more likely with varenicline than placebo (OR 2.27, 95% CI 2.02-2.55) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/46\">",
"     46",
"    </a>",
"    ]. A meta-analysis done for the US Preventive Health Service practice guidelines found that varenicline increased the odds of quitting three-fold compared to placebo (OR 3.1, 95% CI 2.5-3.8) and produced a quit rate of 33 percent at six month follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of initiating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    in perioperative patients has also been evaluated. The preoperative assessment is a good time to motivate ambivalent smokers to quit. In a small randomized trial, 286 patients scheduled for elective noncardiac surgery were randomly assigned to varenicline or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/47\">",
"     47",
"    </a>",
"    ]. All patients received counselling regarding smoking cessation. Preoperative treatment with varenicline improved the abstinence rate at 12 months (36.4 versus 25.2 percent, RR 1.45, 95% CI: 1.01-2.07).",
"   </p>",
"   <p>",
"    Three randomized trials also found",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    to be superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. The two largest randomized trials (n=2052) used identical designs and compared varenicline 1 mg twice daily, bupropion 150 mg twice daily, and placebo for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The primary endpoint of four-week continuous abstinence rate at the end of drug treatment (weeks 9 through 12) was higher with varenicline than with bupropion or placebo in both trials (44 versus 30 and 18 percent, respectively). Continuous abstinence from weeks 9 through 52 was also higher with varenicline (approximately 23 versus 16 and 9 percent, respectively; this difference versus bupropion was statistically significant in one trial and borderline significant in the other trial).",
"   </p>",
"   <p>",
"    Other studies have also compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    with nicotine replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an open-label randomized trial in 757 smokers, the four-week continuous abstinence rate at the end of treatment was higher for the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"       varenicline",
"      </a>",
"      group compared to the nicotine patch group (56 versus 43 percent, OR 1.70, 95% CI 1.26-2.28) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/49\">",
"       49",
"      </a>",
"      ]. The difference between groups in continuous abstinence rates through week 52 narrowed and was not statistically significant (26 versus 20 percent).",
"     </li>",
"     <li>",
"      In a cohort study of 412 smokers who had their choice of available pharmacotherapies, the short-term smoking cessation rate, measured four weeks after the quit date, was higher for smokers who chose to take",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"       varenicline",
"      </a>",
"      compared to a historical control of smokers who chose nicotine replacement prior to the availability of varenicline (72 versus 61 percent, OR 1.7, 95% CI 1.1-2.7) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2012 meta-analysis included the open-label RCT and one other small open-label trial [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/50\">",
"     50",
"    </a>",
"    ] and found no statistically-significant difference in abstinence at 24 weeks with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    or NRT (RR 1.13, CI 0.94-1.35) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/46\">",
"     46",
"    </a>",
"    ]. Additional studies are needed to determine the relative efficacy of varenicline and nicotine replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/36\">",
"     36",
"    </a>",
"    ]. No trial has yet directly compared the efficacy of varenicline with combination NRT. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346565406\">",
"    <span class=\"h3\">",
"     Dosing and duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    is 0.5 mg daily for three days, then 0.5 mg twice daily for four days, and then 1 mg twice daily for the remainder of a 12-week course. Because varenicline undergoes no liver metabolism, it has few interactions with other drugs. However, varenicline is excreted almost entirely by the kidney and requires a dose reduction in individuals with moderate renal insufficiency.",
"   </p>",
"   <p>",
"    Smokers are instructed to quit one week after starting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    , by which time stable blood levels are achieved. It is possible that a longer preloading period prior to the quit date may be more effective in achieving abstinence. In one trial of 101 smokers, abstinence rates at 12 weeks were higher among those randomly assigned to varenicline for four weeks before the quit date compared to those assigned to three weeks of placebo followed by one week of varenicline (47 versus 21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/51\">",
"     51",
"    </a>",
"    ]. Larger trials with longer follow-up periods are needed to determine whether a longer preloading period leads to improved abstinence rates.",
"   </p>",
"   <p>",
"    Patients who have successfully quit at 12 weeks can be continued on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    for an additional 12 weeks. One randomized trial tested the benefit of a longer course of varenicline to prevent smoking relapse among 1236 individuals who had quit smoking after an initial 12-week course [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/52\">",
"     52",
"    </a>",
"    ]. Smokers treated with varenicline for an additional 12 weeks had higher rates of continuous abstinence during weeks 13 through 24 (71 versus 50 percent) as well as during weeks 13 through 52 (44 versus 37 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13311201\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two main safety concerns with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    are neuropsychiatric and cardiovascular side effects. Safety reports reinforce the importance of careful follow-up of smokers started on varenicline. As with other smokers, we recommend that a follow-up visit or a telephone call be scheduled within one week after starting the drug to monitor for adverse effects and provide reinforcement for smoking cessation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link&amp;anchor=H13313727#H13313727\">",
"     \"Overview of smoking cessation management in adults\", section on 'Follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the FDA recommendation that patients be told to contact the office and stop the drug if they or their family notice any unusual behavior or mood symptoms, as well as any new or worsening symptoms of CVD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13311208\">",
"    <span class=\"h4\">",
"     Neuropsychiatric effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2008, the FDA reported \"a possible association between suicidal events and the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    ,\" based upon review of post-marketing reports [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/35\">",
"     35",
"    </a>",
"    ]. Cases were reported even in individuals with no history of psychiatric disease and without concomitant psychiatric medications. Patients should be monitored for neuropsychiatric symptoms including changes in behavior, hostility, agitation, depressed mood, suicidal ideation, and suicide attempts. (See",
"    <a class=\"local\" href=\"#H13311180\">",
"     'Bupropion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A review of case reports from the FDA Adverse Event Reporting System from 1998 to 2010 found that, among smoking cessation medications,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    was responsible for 90 percent of 13,243 reported cases of",
"    <span class=\"nowrap\">",
"     suicidal/self-injurious",
"    </span>",
"    behavior or depression, followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    (7 percent), and nicotine replacement (3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/53\">",
"     53",
"    </a>",
"    ]. This study was limited by retrospective data collection that could be affected by over-reporting of adverse events due to extensive media coverage of varenicline. In contrast, a pooled analysis of 10 randomized placebo-controlled trials in 5096 smokers found no association between varenicline and incidence of psychiatric disorders or psychiatric adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/54\">",
"     54",
"    </a>",
"    ]. However, those trials had excluded potentially vulnerable groups of smokers such as those with a history of major depression or other psychiatric disorders. Furthermore, the clinical trials did not have sufficient power to exclude a rare side effect.",
"   </p>",
"   <p>",
"    Interpretation of these reports is complicated because smokers themselves have an increased risk of suicidal behavior, and similar neuropsychiatric symptoms, including depressed mood, anxiety, anger, irritability, and impaired cognitive function, also occur with nicotine withdrawal and can be seen in smokers who quit smoking without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    . When these symptoms occur in a smoker who is on varenicline it is difficult to know whether to attribute them to the drug or to quitting smoking. Stopping cigarette smoking does not explain all of the reported adverse events because some occurred in smokers on varenicline who had not quit smoking.",
"   </p>",
"   <p>",
"    It appears that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    may have serious neuropsychiatric side effects in some patients, but the nature and magnitude of this risk is not yet well defined. We believe the known benefits of stopping smoking outweigh the uncertain but potential risk of using varenicline in most patients. We recommend taking a careful psychiatric history prior to prescribing the drug, avoiding it in smokers with a history of suicidal ideation or a current unstable psychiatric status, and using it with caution, perhaps as a second-line agent, in smokers with current major depression. Other clinicians take a more conservative approach and limit the drug to patients without psychiatric illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13311215\">",
"    <span class=\"h4\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2011, the FDA issued an advisory that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    may increase the risk of adverse cardiovascular events in patients with known CVD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/55\">",
"     55",
"    </a>",
"    ]. This advisory was based upon findings from a trial in which 714 smokers with stable, documented CVD (other than, or in addition to, hypertension) were randomly assigned to varenicline or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/43\">",
"     43",
"    </a>",
"    ]. More patients treated with varenicline had nonfatal myocardial infarction (2 versus 0.9 percent), need for coronary revascularization (2.3 versus 0.9 percent), and a new diagnosis of peripheral vascular disease (1.4 versus 0.9 percent), but these differences were not statistically significant and patients treated with varenicline appeared to have a lower rate of cardiovascular mortality (0.6 versus 1.4 percent) that was also not statistically significant. This same trial showed that varenicline is effective for smoking cessation in patients with CVD. The FDA suggested that the known benefits of varenicline be weighed against potential harms in patients with CVD.",
"   </p>",
"   <p>",
"    A 2012 meta-analysis of 22 randomized trials (N = 9,232) found no statistically significant difference in rates of cardiovascular events with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    or placebo (0.63 percent versus 0.47 percent; risk difference 0.27 percent, 95% CI -0.10 to 0.63 percent); relative risks were also not statistically significant, but calculation of average relative risks was limited as eight trials had no events [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/56\">",
"     56",
"    </a>",
"    ]. Another 2012 meta-analysis of 15 industry-sponsored randomized trials (n=7,002) also showed no statistically significant difference in incidences of major adverse cardiovascular events (within 30 days of ending treatment) with varenicline or placebo (13 [0.31%] versus 6 [0.21%], respectively; HR 1.95, 95% CI 0.79 to 4.82) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/57\">",
"     57",
"    </a>",
"    ]. However, the meta-analysis had limited power to detect a statistically significant difference because of the small total number (19) of cardiovascular events. An earlier meta-analysis, which found a statistically-significantly increased relative risk of events [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/58\">",
"     58",
"    </a>",
"    ], had methodologic limitations related in part to the exclusion of the trials with no events [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/59\">",
"     59",
"    </a>",
"    ]. In a subsequent large prospective cohort study (n = 35,852), there was no increase in the risk of major cardiovascular events in smokers who took varenicline versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    (6.9 cases versus 7.1 cases per 1000 person years) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It appears unlikely that there is a clinically-important increase in cardiovascular events, at least in low-risk patients, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    . Fewer numbers of patients at high risk for acute events were studied. These meta-analyses do not exclude the possibility of a clinically-important increase in a high-risk population, but also does not show that such a risk is real. Varenicline should not be limited in smokers with cardiovascular disease, since the benefits of smoking cessation are certain. However, patients should be counseled to self-monitor for cardiovascular signs and symptoms that are new or worsening, and to get prompt medical care if needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13311222\">",
"    <span class=\"h4\">",
"     Other effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of adverse drug reports to the FDA by the Institute for Safe Medication Practices, a nonprofit medicine-safety group, found an unusually high rate of accidental injuries from road accidents and falls in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/61\">",
"     61",
"    </a>",
"    ]. The FDA issued a public health advisory stating that patients taking varenicline may experience impairment of the ability to drive or operate heavy machinery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/62\">",
"     62",
"    </a>",
"    ]. Whether these effects are causally related to varenicline cannot be determined, but the Federal Aviation Administration (FAA) subsequently prohibited pilots and air traffic controllers from taking the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other frequently reported adverse events included nausea, insomnia, abnormal dreams, visual disturbances, syncope, and moderate to severe skin reactions. A clinical trial demonstrated that the risk of nausea is reduced if the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    is titrated upward [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H346565406\">",
"     'Dosing and duration'",
"    </a>",
"    above.) Nausea can also be minimized by taking varenicline with food and a full glass of water.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     Varenicline",
"    </a>",
"    is safe for use among smokers with COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13311229\">",
"    <span class=\"h2\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other pharmacologic agents have been evaluated as aids to smoking cessation, all of which have less efficacy in comparison to the first-line agents above (",
"    <a class=\"graphic graphic_table graphicRef60067 \" href=\"UTD.htm?25/45/26333\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following medications are recommended as second-line agents for smoking cessation by the US Public Health Service:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"       Nortriptyline",
"      </a>",
"      , a tricyclic antidepressant, has shown modest benefit in randomized, placebo-controlled trials [",
"      <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/29,65-69\">",
"       29,65-69",
"      </a>",
"      ]. Patients receiving nortriptyline were more likely to report side effects including dry mouth and sedation.",
"     </li>",
"     <li>",
"      Despite promising initial studies,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      is now generally regarded as having limited efficacy for smoking cessation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/70-73\">",
"       70-73",
"      </a>",
"      ]. Although a meta-analysis suggested that clonidine was superior to placebo in facilitating smoking cessation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/73\">",
"       73",
"      </a>",
"      ], the majority of individual studies evaluating the drug have not demonstrated statistically significant efficacy. Adverse effects, such as drowsiness, fatigue, and dry mouth, also limit the effectiveness of clonidine as a smoking cessation aid.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following medications have been investigated as smoking cessation aids but lack evidence of efficacy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    safety:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytisine is a plant derivative that, like",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"       varenicline",
"      </a>",
"      , is a partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor. It has been used for smoking cessation in Eastern Europe for decades but is infrequently used elsewhere [",
"      <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/36\">",
"       36",
"      </a>",
"      ]. A meta-analysis concluded that most trials of cytisine were of poor quality, but that there is some evidence it is effective for smoking cessation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/74\">",
"       74",
"      </a>",
"      ]. In a subsequent randomized trial, treatment with cytisine for 25 days increased sustained abstinence rates at 12 months compared to placebo (8.4 versus 2.4 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/75\">",
"       75",
"      </a>",
"      ]. Gastrointestinal side effects were more common in the treatment arm. Further trials of cytisine are needed to assess efficacy and safety, but if they confirm these findings, the drug may offer a low-cost pharmacologic option for settings such as low- and middle-income countries where varenicline use is limited by cost.",
"     </li>",
"     <li>",
"      Selective serotonin reuptake inhibitors (SSRIs) and anxiolytic drugs generally have not been shown to be effective for smoking cessation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/76,77\">",
"       76,77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A novel experimental approach to treating tobacco dependence is a vaccine that causes the body to generate specific anti-nicotine antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/78\">",
"       78",
"      </a>",
"      ]. The antibody binds to nicotine that reaches the bloodstream from smoking cigarettes. The resulting nicotine-antibody complex is too large to cross the blood-brain barrier. Thus, nicotine from tobacco smoke is unable to reach the CNS nicotinic receptors to produce the reinforcing effect of smoking [",
"      <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/79,80\">",
"       79,80",
"      </a>",
"      ]. Theoretically, a decrease in the rewarding effects of nicotine will lead to smoking cessation. At least three companies have taken candidate vaccines into clinical trials.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525960336\">",
"    <span class=\"h1\">",
"     CHOOSING MEDICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All smokers should generally be offered medication for smoking cessation, in addition to behavioral counseling. We regard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    or the combination of patch plus short-acting NRT as roughly equivalent first-line choices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link&amp;anchor=H13313634#H13313634\">",
"     \"Overview of smoking cessation management in adults\", section on 'Choice of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64330924\">",
"    <span class=\"h2\">",
"     Initiating therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The US Public Health Service smoking cessation guidelines do not recommend any one of the first-line agents over another [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/1\">",
"     1",
"    </a>",
"    ]. Instead, it recommends that patient preference, previous experience with the drugs, and medical conditions guide the choice among the first-line drugs (combined nicotine replacement,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    ). Meta-analyses done for the guideline update addressed the question of whether any drug was more effective than the nicotine patch. In this analysis, there was no statistically significant difference between the patch and other nicotine replacement products or bupropion, but varenicline had a higher efficacy than the nicotine patch (OR 1.6, 95% CI 1.3-2.0). A 2012 meta-analysis found no statistically-significant difference in abstinence at 24 weeks with varenicline or NRT (RR 1.13, CI 0.94-1.35) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/46\">",
"     46",
"    </a>",
"    ]. Until further trials are done, we regard varenicline or the combination of patch plus short-acting NRT as roughly equivalent first-line choices. Combination NRT offers a good choice in individuals for whom the safety of varenicline use is a concern (eg, patients with a history of suicidal ideation).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    or single-type nicotine replacement therapy is a reasonable alternative based on cost, patient preferences, comorbid diseases (eg, depression), and side effect profiles. Bupropion may be a good choice for smokers who are especially concerned about post-cessation weight gain, which bupropion blunts temporarily [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All smokers treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    should be monitored for possible adverse neuropsychiatric events. (See",
"    <a class=\"local\" href=\"#H13311208\">",
"     'Neuropsychiatric effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64323787\">",
"    <span class=\"h2\">",
"     Adjusting therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before changing course, we recommend interviewing patients who fail to quit on a drug to ascertain that the drug was used correctly, as this is often not the case. For patients who do not tolerate medication side effects, we suggest lowering the dose or switching to an alternate agent. In patients who are unable to quit with an adequate trial of individual agents or combination nicotine replacement therapy, we suggest using combination pharmacologic therapy. A reasonable combination is one or two forms of nicotine replacement plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link&amp;anchor=H13313734#H13313734\">",
"     \"Overview of smoking cessation management in adults\", section on 'Difficulty quitting and relapse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combinations of drugs appear be more effective than monotherapy, but can also lead to more side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/1,6,7,82\">",
"     1,6,7,82",
"    </a>",
"    ]. In a meta-analysis of three randomized trials, the combination of nicotine patch and sustained-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    was more effective than the patch alone (OR 1.3, 95% CI 1.0-1.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/1\">",
"     1",
"    </a>",
"    ]. In a subsequent randomized trial, treatment with the combination of nicotine patch, nicotine inhaler, and bupropion for up to 6 months was also more effective than transdermal nicotine alone for 10 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/82\">",
"     82",
"    </a>",
"    ]. It is not known whether this effect reflects use of more than one form of NRT, the addition of bupropion, or the longer duration of treatment. Side effects, including insomnia and anxiety, were more common in patients receiving combination therapy.",
"   </p>",
"   <p>",
"    There may be value in combining",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    with either nicotine replacement or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    , but the safety and efficacy of these combinations have not been well-established. A phase II clinical trial suggests that combining varenicline with bupropion may be efficacious and safe [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/83\">",
"     83",
"    </a>",
"    ]. Similarly, there may be improved efficacy when varenicline is combined with NRT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/85,86\">",
"     85,86",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?17/13/17626/abstract/68\">",
"     68",
"    </a>",
"    ], randomized trials have found that combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    and nicotine replacement therapy is no more effective than nicotine replacement therapy alone.",
"   </p>",
"   <p>",
"    For patients who successfully quit but experience subsequent relapse, we suggest that patients be restarted on the pharmacologic agent that previously worked for the patient. This strategy may be enhanced with more intensive behavioral support",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by combining therapy with another medication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"     \"Smoking cessation counseling strategies in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14901426\">",
"    <span class=\"h1\">",
"     LIMITATIONS OF CLINICAL TRIAL DATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical trial evidence supporting the efficacy of pharmacotherapy is strong but has some limitations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Study participants are likely to be highly motivated, and they may be more likely to continue with drug therapy compared to the average smoker seen in clinical practice.",
"     </li>",
"     <li>",
"      Both drug and placebo arms receive much more intensive counseling than typically occurs in most practice settings. How the drug performs in routine medical practice, where far less counseling support is provided, is not yet known.",
"     </li>",
"     <li>",
"      Trials typically excluded patients with significant comorbid conditions. Thus, quit rates in both the drug and placebo arms are likely to be higher than found in most clinical settings. Subsequent studies have called into question the safety of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"       varenicline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      in patients with psychiatric and cardiovascular disease. (See",
"      <a class=\"local\" href=\"#H13311201\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       \"Patient information: Quitting smoking (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=see_link\">",
"       \"Patient information: Cough in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       \"Patient information: Quitting smoking (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13314646\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that smokers be managed with a combination of behavioral support and pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The combination of counseling and pharmacologic treatment can produce higher quit rates than either one alone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link&amp;anchor=H13313634#H13313634\">",
"       \"Overview of smoking cessation management in adults\", section on 'Choice of treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=see_link\">",
"       \"Smoking cessation counseling strategies in primary care\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The most effective pharmacologic therapies used for smoking cessation include nicotine replacement,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"       varenicline",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H13314630\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"       varenicline",
"      </a>",
"      or combined nicotine replacement (a patch plus a short-acting form such as the gum or lozenge) as first line pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Combination nicotine replacement therapy is a good choice in individuals for whom the safety of varenicline is a concern (eg, history of suicidal ideation).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       Bupropion",
"      </a>",
"      or single-type nicotine replacement therapy is a reasonable alternative based on cost, patient preferences, comorbid diseases, and side effect profiles. Bupropion may be a good choice for smokers who are especially concerned about post-cessation weight gain, which bupropion blunts temporarily. (See",
"      <a class=\"local\" href=\"#H525960336\">",
"       'Choosing medication'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Patients who do not tolerate the side effects of one pharmacologic agent can have the dose lowered or be switched to an alternate agent. Before changing course, patients who fail to quit on a drug should be interviewed to determine that the drug was used correctly, as this is often not the case. (See",
"      <a class=\"local\" href=\"#H64323787\">",
"       'Adjusting therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who are unable to quit with individual agents or combination nicotine replacement therapy, we suggest using combination pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A reasonable combination is one or two forms of nicotine replacement therapy plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      . There may be value in combining",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"       varenicline",
"      </a>",
"      with either nicotine replacement or bupropion, but the safety and efficacy of these combinations have not been well-established. (See",
"      <a class=\"local\" href=\"#H64323787\">",
"       'Adjusting therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link&amp;anchor=H13313734#H13313734\">",
"       \"Overview of smoking cessation management in adults\", section on 'Difficulty quitting and relapse'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that patients who successfully quit but experience relapse be treated with the pharmacologic agent that previously worked for the patient (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This strategy may be enhanced with more intensive behavioral support or by combining therapy with another medication. (See",
"      <a class=\"local\" href=\"#H64323787\">",
"       'Adjusting therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. US Department of Health and Human Services 2008. Available at: www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf (Accessed on October 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/2\">",
"      Rigotti NA. Clinical practice. Treatment of tobacco use and dependence. N Engl J Med 2002; 346:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/3\">",
"      Hajek P, West R, Foulds J, et al. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999; 159:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/4\">",
"      Cepeda-Benito A, Reynoso JT, Erath S. Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women. J Consult Clin Psychol 2004; 72:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/5\">",
"      Perkins KA, Donny E, Caggiula AR. Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob Res 1999; 1:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/6\">",
"      Smith SS, McCarthy DE, Japuntich SJ, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med 2009; 169:2148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/7\">",
"      Piper ME, Smith SS, Schlam TR, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry 2009; 66:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/8\">",
"      Alpert HR, Connolly GN, Biener L. A prospective cohort study challenging the effectiveness of population-based medical intervention for smoking cessation. Tob Control 2013; 22:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/9\">",
"      Daughton DM, Fortmann SP, Glover ED, et al. The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day. Prev Med 1999; 28:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/10\">",
"      Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/11\">",
"      Murray RP, Bailey WC, Daniels K, et al. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest 1996; 109:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/12\">",
"      Ford CL, Zlabek JA. Nicotine replacement therapy and cardiovascular disease. Mayo Clin Proc 2005; 80:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/13\">",
"      Dautzenberg B, Nides M, Kienzler JL, Callens A. Pharmacokinetics, safety and efficacy from randomized controlled trials of 1 and 2 mg nicotine bitartrate lozenges (Nicotinell). BMC Clin Pharmacol 2007; 7:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/14\">",
"      Schneider NG, Olmstead R, Mody FV, et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction 1995; 90:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/15\">",
"      Hays JT, Ebbert JO. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs 2010; 70:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/16\">",
"      T&oslash;nnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J 1999; 13:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/17\">",
"      Schnoll RA, Patterson F, Wileyto EP, et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med 2010; 152:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/18\">",
"      Daughton DM, Heatley SA, Prendergast JJ, et al. Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. A randomized, placebo-controlled, double-blind study. Arch Intern Med 1991; 151:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/19\">",
"      Fant RV, Henningfield JE, Shiffman S, et al. A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem Behav 2000; 67:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/20\">",
"      Benowitz NL. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addition. N Engl J Med 1988; 319:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/21\">",
"      Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA 1999; 281:72.",
"     </a>",
"    </li>",
"    <li>",
"     Nicotrol NS&reg; Product Information. In: Physician's Desk Reference 1998, Medical Economics, Montvale, NJ 1998.",
"    </li>",
"    <li>",
"     file://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000146.pub4/abstract (Accessed on December 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/24\">",
"      Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; :CD000031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/25\">",
"      Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/26\">",
"      Fossati R, Apolone G, Negri E, et al. A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. Arch Intern Med 2007; 167:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/27\">",
"      Ahluwalia JS, Harris KJ, Catley D, et al. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. JAMA 2002; 288:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/28\">",
"      Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003; 24:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/29\">",
"      Wagena EJ, Knipschild PG, Huibers MJ, et al. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med 2005; 165:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/30\">",
"      Planer D, Lev I, Elitzur Y, et al. Bupropion for smoking cessation in patients with acute coronary syndrome. Arch Intern Med 2011; 171:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/31\">",
"      Eisenberg MJ, Grandi SM, Gervais A, et al. Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. J Am Coll Cardiol 2013; 61:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/32\">",
"      Rigotti NA, Thorndike AN, Regan S, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med 2006; 119:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/33\">",
"      Swan GE, McAfee T, Curry SJ, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med 2003; 163:2337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/34\">",
"      Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med 2001; 135:423.",
"     </a>",
"    </li>",
"    <li>",
"     The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics): suicidal ideation and behavior. FDA Drug Safety Newsletter 2009; 2:1. Available at: file://www.fda.gov/downloads/Drugs/DrugSafety/DrugSafetyNewsletter/ucm107318.pdf (Accessed on September 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/36\">",
"      Hays JT, Ebbert JO. Varenicline for tobacco dependence. N Engl J Med 2008; 359:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/37\">",
"      Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48:3474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/38\">",
"      Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for nicotine dependence. CA Cancer J Clin 2005; 55:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/39\">",
"      Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/40\">",
"      Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/41\">",
"      Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006; 166:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/42\">",
"      Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006; 166:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/43\">",
"      Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010; 121:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/44\">",
"      Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007; 29:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/45\">",
"      Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007; 29:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/46\">",
"      Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012; 4:CD006103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/47\">",
"      Wong J, Abrishami A, Yang Y, et al. A perioperative smoking cessation intervention with varenicline: a double-blind, randomized, placebo-controlled trial. Anesthesiology 2012; 117:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/48\">",
"      Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008; 103:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/49\">",
"      Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008; 63:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/50\">",
"      Tsukahara H, Noda K, Saku K. A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study). Circ J 2010; 74:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/51\">",
"      Hajek P, McRobbie HJ, Myers KE, et al. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. Arch Intern Med 2011; 171:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/52\">",
"      Tonstad S, T&oslash;nnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/53\">",
"      Moore TJ, Furberg CD, Glenmullen J, et al. Suicidal behavior and depression in smoking cessation treatments. PLoS One 2011; 6:e27016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/54\">",
"      Tonstad S, Davies S, Flammer M, et al. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf 2010; 33:289.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm259161.htm (Accessed on June 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/56\">",
"      Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012; 344:e2856.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm330367.htm (Accessed on December 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/58\">",
"      Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011; 183:1359.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/07/WC500109177.pdf (Accessed on May 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/60\">",
"      Svanstr&ouml;m H, Pasternak B, Hviid A. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ 2012; 345:e7176.",
"     </a>",
"    </li>",
"    <li>",
"     www.ismp.org/docs/vareniclineStudy.asp (Accessed on October 17, 2011).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Public Health Advisory: Important Information on Chantix (varenicline). file://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm077547.htm (Accessed on September 20, 2011).",
"    </li>",
"    <li>",
"     www.pfizer.com/files/products/uspi_chantix.pdf (Accessed on October 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/64\">",
"      Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011; 139:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/65\">",
"      Roddy E. Bupropion and other non-nicotine pharmacotherapies. BMJ 2004; 328:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/66\">",
"      Prochazka AV, Weaver MJ, Keller RT, et al. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998; 158:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/67\">",
"      Hall SM, Humfleet GL, Reus VI, et al. Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry 2002; 59:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/68\">",
"      Prochazka AV, Kick S, Steinbrunn C, et al. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch Intern Med 2004; 164:2229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/69\">",
"      Hall SM, Reus VI, Mu&ntilde;oz RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998; 55:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/70\">",
"      Glassman AH, Jackson WK, Walsh BT, et al. Cigarette craving, smoking withdrawal, and clonidine. Science 1984; 226:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/71\">",
"      Prochazka AV, Petty TL, Nett L, et al. Transdermal clonidine reduced some withdrawal symptoms but did not increase smoking cessation. Arch Intern Med 1992; 152:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/72\">",
"      Covey LS, Sullivan MA, Johnston JA, et al. Advances in non-nicotine pharmacotherapy for smoking cessation. Drugs 2000; 59:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/73\">",
"      Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev 2004; :CD000058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/74\">",
"      Etter JF. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med 2006; 166:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/75\">",
"      West R, Zatonski W, Cedzynska M, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011; 365:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/76\">",
"      Hughes JR, Stead LF, Lancaster T. Anxiolytics for smoking cessation. Cochrane Database Syst Rev 2000; :CD002849.",
"     </a>",
"    </li>",
"    <li>",
"     Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Available at: www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf (Accessed on September 30, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/78\">",
"      Hartmann-Boyce J, Cahill K, Hatsukami D, Cornuz J. Nicotine vaccines for smoking cessation. Cochrane Database Syst Rev 2012; 8:CD007072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/79\">",
"      Carrera MR, Ashley JA, Hoffman TZ, et al. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem 2004; 12:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/80\">",
"      LeSage MG, Keyler DE, Hieda Y, et al. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology (Berl) 2006; 184:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/81\">",
"      Parsons AC, Shraim M, Inglis J, et al. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev 2009; :CD006219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/82\">",
"      Steinberg MB, Greenhaus S, Schmelzer AC, et al. Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. Ann Intern Med 2009; 150:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/83\">",
"      Ebbert JO, Croghan IT, Sood A, et al. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res 2009; 11:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/84\">",
"      Ebbert JO, Burke MV, Hays JT, Hurt RD. Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res 2009; 11:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/85\">",
"      Hall SM, Humfleet GL, Reus VI, et al. Extended nortriptyline and psychological treatment for cigarette smoking. Am J Psychiatry 2004; 161:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/13/17626/abstract/86\">",
"      Aveyard P, Johnson C, Fillingham S, et al. Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: pragmatic randomised controlled trial. BMJ 2008; 336:1223.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16635 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-2522EA1FE6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_13_17626=[""].join("\n");
var outline_f17_13_17626=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13314646\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13311124\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13314630\">",
"      MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13311131\">",
"      Nicotine replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H606502088\">",
"      - Efficacy, dosing, duration, safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13311138\">",
"      Transdermal nicotine patch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13311145\">",
"      Nicotine gum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13311152\">",
"      Nicotine lozenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13311159\">",
"      Nicotine inhaler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13311166\">",
"      Nicotine nasal spray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H606502060\">",
"      Combination nicotine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13311180\">",
"      Bupropion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H346565385\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H346565378\">",
"      - Dosing and duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13311187\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13311194\">",
"      Varenicline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H346565392\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H346565406\">",
"      - Dosing and duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13311201\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13311208\">",
"      Neuropsychiatric effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13311215\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13311222\">",
"      Other effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13311229\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H525960336\">",
"      CHOOSING MEDICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64330924\">",
"      Initiating therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64323787\">",
"      Adjusting therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14901426\">",
"      LIMITATIONS OF CLINICAL TRIAL DATA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13314646\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/16635\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16635|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/45/26333\" title=\"table 1\">",
"      Smoking Abstinence Rates",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18968?source=related_link\">",
"      Benefits and risks of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/23/30073?source=related_link\">",
"      Cardiovascular effects of nicotine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/59/7098?source=related_link\">",
"      Overview of the non-acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=related_link\">",
"      Patient information: Cough in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12904?source=related_link\">",
"      Smoking cessation counseling strategies in primary care",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_13_17627="Assessment tools for fatigue in patients with serious illness";
var content_f17_13_17627=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PALC%2F86228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PALC%2F86228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessment tools for fatigue in patients with cancer and/or other serious life-threatening conditions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Fatigue severity scale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Fatigue questionnaire",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Multidimensional fatigue inventory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Multidimensional fatigue symptom inventory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Revised Piper fatigue scale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Revised Schwartz cancer fatigue scale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Brief fatigue inventory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Multidimensional assessment of fatigue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Fatigue symptom inventory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;11. Functional Assessment of Cancer Therapy-Fatigue (FACT-F)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12. Edmonton Symptom Assessment Scale (ESAS)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_13_17627=[""].join("\n");
var outline_f17_13_17627=null;
var title_f17_13_17628="Guidelines for surgery in asymptomatic PHPT";
var content_f17_13_17628=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F63054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F63054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of new and old guidelines for parathyroid surgery in asymptomatic PHPT*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Measurement",
"       </td>",
"       <td class=\"subtitle1\">",
"        1990",
"       </td>",
"       <td class=\"subtitle1\">",
"        2002",
"       </td>",
"       <td class=\"subtitle1\">",
"        2008",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum calcium (&gt;upper limit of normal)",
"       </td>",
"       <td>",
"        1-1.6 mg/dl (0.25-0.4 mmol/liter)",
"       </td>",
"       <td>",
"        1.0 mg/dl (0.25 mmol/liter)",
"       </td>",
"       <td>",
"        1.0 mg/dl (0.25 mmol/liter)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24-h urine for calcium",
"       </td>",
"       <td>",
"        &gt;400 mg/d (&gt;10 mmol/d)",
"       </td>",
"       <td>",
"        &gt;400 mg/d (&gt;10 mmol/d)",
"       </td>",
"       <td>",
"        Not indicated&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Creatinine clearance (calculated)",
"       </td>",
"       <td>",
"        Reduced by 30 percent",
"       </td>",
"       <td>",
"        Reduced by 30 percent",
"       </td>",
"       <td>",
"        Reduced to &lt;60 ml/min",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BMD",
"       </td>",
"       <td>",
"        Z-score &lt;-2.0 in forearm",
"       </td>",
"       <td>",
"        T-score &lt;-2.5 at any site&Delta;",
"       </td>",
"       <td>",
"        T-score &lt;-2.5 at any site&Delta; and/or previous fracture fragility&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age (yr)",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"       <td>",
"        &lt;50",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Surgery is also indicated in patients for whom medical surveillance is neither desired nor possible.",
"     <br>",
"      &bull; Some physicians still regard 24-h urinary calcium excretion &gt;400 mg as an indication for surgery.",
"      <br>",
"       &Delta; Lumbar spine, total hip, femoral neck, or 33 percent radius (1/3 site). This recommendation is made recognizing that other skeletal features may contribute to fracture risk in PHPT and that the validity of this cut-point for any site vis-a-vis fracture risk prediction has not been established in PHPT.",
"       <br>",
"        &loz; Consistent with the position established by the International Society for Clinical Densitometry, the use of Z-scores instead of T-scores is recommended in evaluating BMD in premenopausal women and men younger than 50 yr.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bilezikian JP, Khan A, Potts J. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop. J Clin Endocrinol Metab 2009; 94:335. file://jcem.endojournals.org/. Copyright &copy; 2009 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_13_17628=[""].join("\n");
var outline_f17_13_17628=null;
var title_f17_13_17629="Risk-adapted treatment of newly diagnosed HL in children";
var content_f17_13_17629=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk-adapted treatment of newly diagnosed Hodgkin lymphoma in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Low risk disease*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Four cycles of VAMP (vinblastine, doxorubicin, methotrexate, prednisone) plus LD-IFRT administered after the second cycle of chemotherapy",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Four cycles of COPP (cyclophosphamide, vincristine, procarbazine, prednisone)/ABV (doxorubicin, bleomycin, vinblastine) plus LD-IFRT",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ABVE (doxorubicin, bleomycin, vinblastine, etoposide), administered for two to four courses depending on response, followed by LD-IFRT",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        OEPA (vincristine, etoposide, prednisone, doxorubicin; for males) or OPPA (vincristine, procarbazine, prednisone, doxorubicin; for females) followed by LD-IFRT, depending upon the initial response to chemotherapy",
"        <sup>",
"         [4,5]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intermediate risk disease*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Six cycles of COPP/ABV plus LD-IFRT",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ABVE-PC (doxorubicin, bleomycin, vinblastine, etoposide, prednisone, cyclophosphamide), administered for three to five courses depending upon response, followed by LD-IFRT",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two cycles of OPPA (for males) or OEPA (for females), followed by two cycles of COPP (for females) or COPDAC (cyclophosphamide, vincristine, prednisone, dacarbazine, for males) plus LD-IFRT",
"        <sup>",
"         [4-6]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        High risk disease*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ABVE-PC, administered for three to five courses depending upon response, followed by LD-IFRT",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two cycles of OPPA (for males) or OEPA (for females), followed by two cycles of COPP (for females) or COPDAC (for males) plus LD-IFRT",
"        <sup>",
"         [4-6]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two cycles of cytarabine/etoposide, COPP/ABV, and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) plus LD-IFRT",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Four cycles of BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) with subsequent therapy dependent upon response; rapid responders: four cycles of COPP/ABV without IFRT (for females) or two cycles ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) with IFRT (for males); slow responders: four additional cycles of BEACOPP plus IFRT",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table provides examples of treatment regimens that have been successfully employed in children and adolescents with newly diagnosed Hodgkin lymphoma. A choice among these treatment options is largely based upon physician experience, cancer center preference, and expected toxicities. The determination of preferred therapy for an individual patient should involve a multidisciplinary approach from the time of diagnosis.",
"    <div class=\"footnotes\">",
"     LD: low dose; IFRT: involved field radiation therapy.",
"     <br/>",
"     * For definition refer to UpToDate topics on Hodgkin lymphoma in children and adolescents.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Donaldson SS, Link MP, Weinstein HJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 2007; 25:332.",
"      </li>",
"      <li>",
"       Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20:3765.",
"      </li>",
"      <li>",
"       Tebbi CK, Mendenhall N, London WB, et al. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study. Pediatr Blood Cancer 2006; 46:198.",
"      </li>",
"      <li>",
"       Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 2009; 114:2051.",
"      </li>",
"      <li>",
"       R&uuml;hl U, Albrecht M, Dieckmann K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 2001; 51:1209.",
"      </li>",
"      <li>",
"       Mauz-K&ouml;rholz C, Hasenclever D, D&ouml;rffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 2010; 28:3680.",
"      </li>",
"      <li>",
"       Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood 2011; 117:2596.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_13_17629=[""].join("\n");
var outline_f17_13_17629=null;
var title_f17_13_17630="Time to reperfusion after ischemic stroke predicts outcome";
var content_f17_13_17630=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F50822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F50822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Probability of good clinical outcome over time to technically successful angiographic reperfusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 285px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The graph above shows the probability of a good clinical outcome over time (with 95% confidence bands) for cases with angiographic reperfusion as predicted by unadjusted logistic regression (p = 0.02). In addition, a horizontal line depicting the rate of good clinical outcome for all cases with ICA-T and MCA occlusions on angiogram that did not show significant angiographic reperfusion is provided as a reference.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Khatri P, Abruzzo T, Yeatts SD, et al. Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. Neurology 2009; 73:1066. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_13_17630=[""].join("\n");
var outline_f17_13_17630=null;
var title_f17_13_17631="HALO360 ablation catheter";
var content_f17_13_17631=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    HALO360 ablation catheter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    HALO360 ablation catheter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: B&Acirc;RRX Medical Inc. Copyright &copy; 2011. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_13_17631=[""].join("\n");
var outline_f17_13_17631=null;
